Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Bone and cardiovascular health after menopause
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Prevention does not replace acute assessment
New chest pain, focal neurological deficit, sudden severe breathlessness, a painful swollen leg, collapse or a suspected hip or vertebral fracture needs urgent assessment rather than calculation of long-term risk.
Action: Stabilise the patient, use the relevant acute cardiovascular, thromboembolic or fracture pathway, provide analgesia and falls care where required, and return to preventive planning after the immediate diagnosis is addressed.
Role and principles
Assess bone and cardiovascular risk after menopause, distinguish symptom treatment from disease prevention, and use risk-based lifestyle, imaging and preventive-medicine pathways without inappropriate routine testing.
Oestrogen decline accelerates bone remodelling and contributes to loss of bone mineral density, while ageing, lower muscle mass, falls and comorbidity determine whether that loss becomes a fracture. The menopausal consultation is therefore an opportunity to ask about previous low-trauma fractures, height loss, back pain, falls, parental hip fracture, systemic glucocorticoids, inflammatory disease, malabsorption, low body weight, smoking and alcohol. It is not an instruction to scan every asymptomatic person at the final menstrual period. Risk assessment should determine whether DXA or treatment is likely to change care.
NICE CG146 advises assessing fracture risk in all women aged 65 and over and in younger women when relevant risk factors are present. Untreated premature menopause is a cause of secondary osteoporosis and a major factor in people under 50. FRAX or QFracture estimates ten-year absolute risk within the tools' age ranges. A DXA scan is generally considered when calculated risk lies near an intervention threshold or when a treatment or major clinical factor warrants direct measurement; a normal result does not erase falls risk, and a low result must be interpreted with age and the clinical history.
Assessment and patient selection
Raised fracture risk
Previous fragility fracture, systemic glucocorticoids, falls, parental hip fracture, low BMI, smoking, excess alcohol or secondary osteoporosis supports formal skeletal assessment.
Possible vertebral fracture
New focal back pain, height loss or kyphosis after minor strain can indicate vertebral compression even when there was no memorable fall.
Modifiable vascular burden
Smoking, hypertension, dyslipidaemia, diabetes, inactivity and harmful alcohol use often contribute more actionable risk than the menopause label itself.
Risk-tool exception
Established cardiovascular disease, type 1 diabetes, significant chronic kidney disease or familial hypercholesterolaemia requires its specific guideline pathway rather than routine QRISK triage.
Premature oestrogen loss
Menopause before 40 or prolonged untreated hypogonadism changes bone and vascular prevention and warrants a dedicated POI or specialist pathway.
Red flags requiring action
Central chest pressure, acute breathlessness, syncope or focal neurological symptoms requires emergency cardiovascular or stroke assessment regardless of menopausal status.
Sudden unilateral leg swelling or pleuritic pain with hypoxaemia raises concern for venous thromboembolism and must not be attributed to HRT anxiety alone.
Hip pain after a low-energy fall, new inability to bear weight or acute spinal pain with height loss suggests fragility fracture and needs prompt imaging.
Baseline assessment
01FRAX or QFracture assessmentFirst step
Why
Estimate ten-year absolute fragility-fracture risk when age or clinical factors justify formal assessment.
Interpretation and limitations
Use the tool only within its validated range and recognise that multiple fractures, high-dose glucocorticoids and secondary osteoporosis can make the calculated value an underestimate.
02DXA of hip and lumbar spine
Why
Measure bone mineral density when the result will refine risk or guide an osteoporosis or treatment decision.
Interpretation and limitations
Interpret T-scores, Z-scores, artefact and clinical risk together; a scan is not a stand-alone screening test for every person at menopause.
03Secondary-bone-cause panel
Why
Investigate a plausible reversible contributor in someone with fracture, unexpectedly low density or a suggestive history.
Interpretation and limitations
Calcium, renal, liver, thyroid, vitamin D, coeliac or haematological testing is selected from the presentation rather than ordered as a universal menopause panel.
04QRISK3 assessment
Why
Estimate ten-year cardiovascular risk in eligible adults without established cardiovascular disease.
Interpretation and limitations
Check that the person fits the tool's population, enter current data accurately and discuss absolute risk; use disease-specific guidance when a high-risk condition makes scoring inappropriate.
Interventions
01Skeletal triageAssess before scanningFirst stepAge, fracture history or a clinical risk factor raises concern about fragility fracture.+
1Take a fracture, falls, medicine, menstrual and secondary-cause history and examine height, gait and relevant focal symptoms.
2Use FRAX or QFracture when appropriate, arranging DXA when risk lies near an intervention threshold or a major factor creates a specific indication.
3Treat established osteoporosis or fragility fracture through the relevant pathway while adding exercise, nutrition and falls measures tailored to ability.
02Vascular reviewCalculate and modify riskPreventive review identifies cardiovascular risk factors without an acute presentation.+
1Record smoking, blood pressure, weight, diabetes, renal status, family history, full lipids and relevant comorbidity before estimating risk.
2
Targets, monitoring and follow-up
Reassess fracture risk after a fragility fracture, a substantial change in risk factors or a new treatment that affects bone, rather than repeating tools at arbitrary short intervals.
Review blood pressure, lipids, diabetes measures, smoking and adherence at intervals defined by the relevant cardiovascular guideline and the treatment chosen.
Ask about new falls, height loss, back pain, mobility and strength because functional change can be clinically important before a scheduled bone-density review.
During HRT review, revisit route, bleeding, thrombotic or arterial events and whether the original symptom benefit still outweighs risk; keep prevention medicines conceptually separate.
Use shared goals for activity, resistance training, diet and smoking cessation, adapting the plan for disability, frailty, pain, cultural needs and access barriers.
Special situations
Risk comes before DXA
NICE uses clinical fracture-risk assessment to decide who benefits from bone-density measurement rather than treating DXA as universal menopause screening.
Falls change fracture probability
Bone density is only one determinant of fracture, so strength, balance, medicines and home hazards remain relevant even when DXA is reassuring.
HRT goals must be named
Symptom treatment and replacement for POI are legitimate contexts, whereas cardiovascular or dementia prevention alone is not a NICE indication.
Absolute risk supports decisions
QRISK3 and fracture tools are most useful when their numerical outputs are explained alongside uncertainty and the likely benefit of each intervention.
Early menopause is different
Long exposure to oestrogen deficiency before the usual menopause age warrants proactive hormone, bone and cardiovascular planning rather than average-age reassurance.
Common pitfalls
01
Ordering routine DXA for every person at natural menopause without assessing whether the result will change management.
02
Using a normal bone-density result to ignore falls, glucocorticoids, low weight or a previous fragility fracture.
03
Prescribing calcium supplements as a substitute for adequate nutrition, resistance activity, falls reduction or indicated osteoporosis therapy.
04
Offering systemic HRT solely to prevent myocardial infarction, stroke, dementia or recurrent cardiovascular disease.
05
Applying QRISK3 to established cardiovascular disease or another excluded high-risk group instead of using its disease-specific pathway.
06
Describing later-life disease as inevitable after menopause in a way that obscures modifiable risk and shared decision making.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Selecting fracture assessment
A 58-year-old with no fracture history asks for routine bone screening at a menopause review. She has used repeated oral prednisolone courses and currently smokes. What is the best initial approach?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Bone health is broader than calcium tablets. Encourage varied nutrition with adequate protein and calcium, vitamin D intake appropriate to UK public-health advice, weight-bearing impact where safe, progressive resistance work and balance training when falls are a concern. Stop smoking and avoid harmful alcohol use. Review vision, footwear, sedating medicines, environmental hazards and conditions affecting gait. Calcium or vitamin D supplements should address inadequate intake or a defined indication, not substitute for exercise, falls prevention or osteoporosis treatment when fracture risk is high.
Cardiovascular risk rises with age and clustering of familiar modifiable factors, not because menopause creates a single diagnostic threshold. Ask about smoking, blood pressure, diabetes, renal disease, migraine, inflammatory disease, severe mental illness, family history and pregnancy-associated vascular history. Measure a full lipid profile and other baseline variables when performing a formal assessment. NICE NG238 uses QRISK3 for adults aged 25 to 84 without established cardiovascular disease, with separate pathways for established disease, type 1 diabetes, significant chronic kidney disease and familial lipid disorders.
HRT and prevention must not be conflated. NICE states that combined or oestrogen-only HRT should not be offered for primary or secondary prevention of cardiovascular disease and should not be used for dementia prevention. In someone using HRT for menopausal symptoms, the route and personal cardiovascular or thrombotic history still shape safety: specialist menopause input is appropriate after coronary heart disease or stroke, and transdermal oestrogen may be favoured when venous-thromboembolism risk is raised. This does not replace statins, antihypertensives or antiplatelet treatment when those are indicated independently.
A useful review translates risk into action and avoids deterministic counselling. Record the person's goals, calculate absolute risk when indicated, explain uncertainty, and address the largest modifiable contributors first. Reassess after a major health change, fracture, new glucocorticoid course, HRT change or development of vascular disease. Early menopause and POI require a different replacement-hormone perspective because untreated oestrogen deficiency begins years before the usual menopause age; they should not be managed by simply applying average-age prevention assumptions.
Key points
Menopause is a useful point to review smoking, blood pressure, weight, diabetes, lipids, alcohol, activity, falls and fracture history, but it does not make every person high risk.
Advise regular weight-bearing and muscle-strengthening activity, adequate dietary calcium and vitamin D, smoking cessation and alcohol within UK low-risk guidance.
NICE recommends fracture-risk assessment for all women aged 65 or over and for younger people when risk factors such as fragility fracture, glucocorticoids, low BMI, smoking or untreated premature menopause are present.
Use FRAX or QFracture within their validated age ranges; do not order routine DXA without first considering clinical risk, except where a major factor creates a specific indication.
Use QRISK3 for eligible adults aged 25 to 84 without established cardiovascular disease, while recognising groups in whom the score may underestimate risk or is not the correct pathway.
Do not prescribe systemic HRT solely for primary or secondary prevention of cardiovascular disease or for prevention of dementia.
HRT reduces fragility-fracture risk while it is taken, but a symptom-treatment decision should still use the person's overall benefits, harms, anatomy and preferences.
Treat hypertension, diabetes, dyslipidaemia, tobacco dependence and established osteoporosis according to their own guidelines rather than labelling them inevitable consequences of menopause.
Severe back pain with weakness, saddle sensory change or bladder or bowel dysfunction requires emergency assessment for cord or cauda-equina compression.
Multiple fractures, a vertebral fracture, marked low weight or prolonged systemic glucocorticoid exposure indicates high skeletal risk requiring active assessment rather than lifestyle advice alone.
05Blood pressure, full lipid profile and diabetes status
Why
Identify modifiable cardiovascular factors and provide the inputs needed for a complete preventive assessment.
Interpretation and limitations
Confirm persistent hypertension correctly, consider secondary dyslipidaemia and use HbA1c or glucose according to diabetes guidance rather than attributing abnormalities to menopause.
Use QRISK3 only for eligible people and explain absolute risk, uncertainty and how individual interventions change that risk.
3Prioritise smoking cessation, blood-pressure and diabetes control, physical activity, diet and guideline-directed lipid lowering, then review response.
03Hormone boundarySeparate symptoms from preventionHRT is being considered or reviewed alongside bone or cardiovascular concerns.+
1Clarify whether the treatment goal is relief of menopausal symptoms, replacement for POI, fracture-risk reduction during use or management of an established disease.
2Do not use HRT solely to prevent cardiovascular disease or dementia, and do not withhold independently indicated preventive medicines because HRT is being taken.
3Seek appropriate menopause, cardiology, haematology or bone expertise when prior vascular disease, high thrombosis risk, POI or complex osteoporosis changes the balance.